Find out more about MSF's operations, mission, and it's principles.
Ahead of GAVI’s progress review in Stockholm, Médecins Sans Frontières/Doctors Without Borders (MSF) is calling for four key policy changes to reduce the number of children missing out on vaccinations globally (22.6 million in 2012).
“We think GAVI should be commended for many of its accomplishments over the last decade, but we also think it’s very important for GAVI to take a close and critical look at what it can improve going forward”, said Kate Elder, Vaccines Policy Advisor at MSF’s Access Campaign.
“We believe an ambitious, inclusive GAVI that will fight hard to shape markets, products and prices, is essential in helping the world meet its immunisation targets and preventing disease in the most vulnerable.”
“We fully support GAVI’s mission of bringing new vaccines to children in developing countries, but we think the alliance could improve its work so that more children are protected from childhood killers,” said Dr. Manica Balasegaram, Executive Director of MSF’s Access Campaign.
“Humanitarian organisations are still not able to access vaccines at the GAVI price, which would allow them to act swiftly in emergencies. Vaccine prices overall are still too expensive for countries to afford long-term, and GAVI is not doing enough to support the vaccination needs of older children.”
MSF has identified four key areas where changes at GAVI could make an important difference:
It took 11 months for MSF to navigate its way through bureaucratic hurdles to finally obtain the pneumococcal vaccine for use in a refugee camp in South Sudan where there was high child mortality.
The fact that GAVI does not include non-governmental and humanitarian organisations in its price negotiations has resulted in refugees missing out on the benefits of new vaccines. GAVI should open its prices to NGOs and urgently move to develop a policy for facilitating use of new vaccines amongst refugee and crisis-affected populations.
For example, Congo will lose GAVI support at the end of 2015, and will be forced to pay 20 times more for new vaccines than it pays for the traditional vaccines. These high prices jeopardise the sustainability of immunisation programmes and could force governments to make tough decisions about which childhood killers they can and cannot afford to protect their children against.
GAVI must do more to bring prices down by negotiating more shrewdly and transparently with the multinational pharmaceutical companies, and by helping speed up the market entry of vaccines from emerging producers.
This means that a child over one who arrives at a clinic and hasn’t completed their immunisation series would not be able to benefit from these life-saving vaccines. This is a missed opportunity to fully protect children against childhood killers, and can often result in deadly outbreaks of preventable diseases. GAVI should revise its support to countries so that they can fully implement WHO recommendations.
The MenAfriVac vaccine against meningitis A was recently re-labelled, making it possible to keep the vaccine at up to 40 degrees C for up to four days, greatly easing the logistics requirements in hot and remote places. More research needs to be done to investigate how other vaccines could potentially follow suit, to make it easier to vaccinate hard-to-reach children.
GAVI must play a more active role in incentivising such efforts so that easier-to-use vaccines can become available.
MSF vaccinated nearly 700,000 people for measles and nearly 500,000 for meningitis in 2012.
Get a deeper insight into the work of MSF by contacting us.